Market Closed -
Other stock markets
|
|
5-day change | 1st Jan Change | |
68.71 USD | +0.50% | -2.65% | -8.15% |
Dec. 08 | Hologic Appoints Essex Mitchell as Chief Operating Officer | MT |
Dec. 08 | Hologic, Inc. Promotes Essex D. Mitchell to Chief Operating Officer | CI |
Financials (USD)
Sales 2024 * | 4B | Sales 2025 * | 4.22B | Capitalization | 16.41B |
---|---|---|---|---|---|
Net income 2024 * | 780M | Net income 2025 * | 842M | EV / Sales 2024 * | 3,97x |
Net cash position 2024 * | 542M | Net cash position 2025 * | 1.6B | EV / Sales 2025 * | 3,51x |
P/E ratio 2024 * | 21,2x | P/E ratio 2025 * | 19,4x | Employees | 6,990 |
Yield 2024 * | - | Yield 2025 * | - | Free-Float | 80.22% |
More Fundamentals
* Assessed data
More news
More recommendations
More press releases
1 day | +0.50% | ||
1 week | -2.65% | ||
Current month | -3.63% | ||
1 month | -3.77% | ||
3 months | -5.61% | ||
6 months | -12.43% | ||
Current year | -8.15% |
1 week
67.59
70.42

1 month
67.59
73.05

Current year
64.02
87.88

1 year
64.02
87.88

3 years
59.78
87.88

5 years
26.49
87.88

10 years
19.91
87.88

Managers | Title | Age | Since |
---|---|---|---|
Chief Executive Officer | 59 | 2013 | |
Karleen Oberton
DFI | Director of Finance/CFO | 53 | 2005 |
Paul Malenchini
CTO | Chief Tech/Sci/R&D Officer | - | 2021 |
Members of the board | Title | Age | Since |
---|---|---|---|
Chief Executive Officer | 59 | 2013 | |
Director/Board Member | 68 | 2017 | |
Director/Board Member | 62 | 2016 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
3.60% | 1 M€ | -9.36% | ||
3.53% | 2 M€ | +7.61% | - | |
3.48% | 34 M€ | +19.86% | - | |
2.29% | 3 M€ | -14.56% |
Date | Price | Change | Volume |
---|---|---|---|
23-12-11 | 68.71 | +0.50% | 1 448 726 |
23-12-08 | 68.37 | -1.23% | 1,672,566 |
23-12-07 | 69.22 | +0.16% | 2,363,544 |
23-12-06 | 69.11 | -0.22% | 1,752,923 |
23-12-05 | 69.26 | -1.87% | 2,062,468 |
Delayed Quote Nasdaq, December 11, 2023 at 03:59 pm EST
More quotes
Hologic, Inc. is the world leader in the design, manufacturing and marketing of diagnostic products, medical imaging systems and surgical products dedicated to women's health. Net sales break down by area of application as follows:
- molecular diagnostics (62.1%): rapid diagnostic tests for human diseases detection (sexually transmitted infections, respiratory diseases, viral diseases, infectious diseases, cancers of the cervix and prostate, etc.) and fetal fibronectin;
- breast health (25.3%): digital mammography and breast biopsy solutions and systems;
- gynecological surgery (10.8%): endometrial ablation devices, minimally invasive intervention systems for the hysteroscopic elimination of targeted intrauterine diseases (including fibroids and polyps). The group also offers fluid management systems for use in hysteroscopic procedures;
- bone health (1.97%): bone imaging systems, bone sonometers and osteodensitometers for bone structure and density, and osteoporotic fractures risk assessment.
Net sales break down by source of revenue between sales of products (86.2%) and services (13.8%).
Net sales are distributed geographically as follows: the United States (71.3%), Europe (18.3%), Asia/Pacific (7.4%) and other (3%).
Calendar
2024-01-30
- Q1 2024 Earnings Release (Projected)
Trading Rating :
Investor Rating :
ESG Refinitiv :
B+
Sell
Buy

Mean consensus
OUTPERFORM
Number of Analysts
19
Last Close Price
68.37USD
Average target price
79.82USD
Spread / Average Target
+16.75%
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-8.15% | 16 409 M $ | |
-10.11% | 189 B $ | |
-16.60% | 161 B $ | |
+18.88% | 109 B $ | |
+19.43% | 80 501 M $ | |
+11.88% | 63 269 M $ | |
-5.74% | 49 971 M $ | |
-5.76% | 41 958 M $ | |
-13.82% | 37 158 M $ | |
+21.84% | 31 193 M $ |